IMMUNIC, INC.
About IMMUNIC, INC.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2014
- $22.0K
- Net income
- -$97.2M
- Total assets
- $24.1M
- Market cap
- $173.9M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $103.2M
- Operating income
- -$103.2M
- Income tax
- $0
- Net income
- -$97.2M
- EPS (basic)
- $-0.62
- EPS (diluted)
- $-0.62
Balance sheet
- Total assets
- $24.1M
- Current assets
- $22.9M
- Total liabilities
- $30.7M
- Current liabilities
- $30.6M
- Shareholders’ equity
- -$6.7M
Cash flow
- Operating cash flow
- -$85.8M
- Investing cash flow
- -$161.0K
- Financing cash flow
- $65.6M
- Net cash flow
- -$20.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $173.9M
- EPS (diluted)
- $-0.62
- Shares outstanding
- 14.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 17, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $97.2M in FY2014.
- Trading 20% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review IMMUNIC, INC..
Write a review
News about IMMUNIC, INC.
News & sentiment via Polygon.io
